Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group phase II trial

Journal of Clinical Oncology

Volumn 22, Issue 24, 2004, Pages 4944-4950

  Alberts, Steven R ^a   Schroeder, Mark ^a   Erlichman, Charles ^a   Steen, Preston D ^a   Foster, Nathan R ^a   Moore Jr , Dennis F ^a   Rowland Jr , Kendrith M ^a   Nair, Suresh ^a   Tschetter, Loren K ^a   Fitch, Tom R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; ISIS 2503; ANTINEOPLASTIC ANTIMETABOLITE; ANTISENSE OLIGONUCLEOTIDE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG TOLERABILITY; FOLLOW UP; HUMAN; IMAGING; LUNG EMBOLISM; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADENOCARCINOMA; ADULT; AGED; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PANCREAS TUMOR; PATHOLOGY; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OLIGONUCLEOTIDES, ANTISENSE; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 16644402183     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.05.034     Document Type: Article

References (18)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003
2. Trede M, Saeger HD, Schwall G, et al: Resection of pancreatic cancer-surgical achievements. Langenbecks Arch Surg 383:121-1288, 1998
3. Cullinan SA, Moertel CG, Fleming TR, et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253:2061-2067, 1985
4. DeCaprio JA, Mayer RJ, Gonin R, et al: Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: Results of a phase II trial. J Clin Oncol 9:2128-2133, 1991
5. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
6. Sirivatanauksorn V, Sirivatanauksorn Y, Lemoine NR: Molecular pattern of ductal pancreatic cancer. Langenbecks Arch Surg 383:105-115, 1998
7. Rebollo A, Martinez AC: Ras proteins: Recent advances and new functions. Blood 94:2971-2980, 1999
8. Seufferlein T, Van Lint J, Liptay S, et al: Transforming growth factor alpha activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations. Gastroenterology 116:1441-1452, 1999
9. Geary RS, Leeds JM, Henry SP, et al: Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des 12:383-393, 1997
10. Monia BP, Johnston JF, Ecker DJ, et al: Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem 267:19954-19962, 1992
11. Adjei AA, Dy GK, Erlichman C, et al: A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 9:115-123, 2003
12. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
13. Fleming TR: One sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151, 1982
14. Duffy D, Santner T: Confidence intervals for a binomial parameter based on multistage tests. Biometrics 43:81-93, 1987
15. Kaplan E, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Cohen SJ, Ho L, Ranganathan S, et al: Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 21:1301-1306, 2003
17. Van Cutsem E, Oettle K, Vervenne W, et al: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer (PC). Proc Am Soc Clin Oncol 21:130a, 2002 (abstr 517)
18. Cunningham CC, Holmlund JT, Geary RS, et al: A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 92:1265-1271, 2001